Ipsen Stock

Ipsen S.A. engages in the research, development, manufacture, and sale of pharmaceutical products worldwide.

The company’s product portfolio includes pharmaceutical products marketed to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology), which are its primary areas of development. It also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular, and cognitive disorders).

SPECIALIST CARE

Oncology

Decapeptyl is a peptide formulation for injection used to treat advanced prostate cancer.

Endocrinology

Somatuline and Somatuline Autogel, are sustained release formulations for injection of a somatostatin analogue peptide, used primarily in the treatment of acromegaly.

NutropinAq is a liquid formulation for daily use of recombinant human growth hormone used primarily in the treatment of growth failure in children and growth hormone deficiency in adults.

Neurology

Dysport is a botulinum neurotoxin type A complex, used notably to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles.

Apokyn is used for the treatment of off episodes (reemergence of Parkinson’s disease symptoms) associated with advanced Parkinson’s disease, namely when the therapeutic effects of the conventional treatment (L-Dopa) diminish.

PRIMARY CARE

Gastroenterology (18.8% of 2008 consolidated sales)

Smecta is a natural clay-based drug used in the treatment of both chronic and acute diarrhoea.

Forlax is a drug based on a linear polyethylene glycol polymer used in the treatment of constipation.

Cognitive Disorders

Tanakan is an oral formulation of EGb 761, extracted from the leaves of the Ginkgo biloba tree, used principally in the treatment of age-related cognitive disorders.

Cardiovascular

Nisis and Nisisco are oral formulations notably containing valsartan, used in the treatment of arterial hypertension.

Ginkor Fort is an oral formulation containing three active substances, including a standardised extract from the leaves of the Ginkgo biloba tree used in the treatment of venous insufficiency of the lower limbs and acute haemorrhoid episodes.

Acquisitions

In 2008, the company completed the acquisition of the rights to Apokyn, and Vernalis’ U.S. Commercial Operations.

In 2008, the company acquired its U.S. subsidiary Vernalis Pharmaceuticals, Inc. and the rights to develop and market Apokyn in the U.S.

Collaboration agreement

In July 2021, Ipsen S.A. and BAKX Therapeutics Inc. have signed a collaboration agreement to research, develop, manufacture and commercialize BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.

History

Ipsen S.A. was founded in 1929.